Amivantamab OK'd for EGFR-Mutant NSCLC

Abstract

The FDA granted accelerated approval to amivantamab, the first treatment for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations. The bispecific antibody drug, which targets EGFR and MET, is also the first agent directed against two tumor antigens to earn the regulatory nod.